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Summary
Objectives: Recent studies have demonstrated that not only plasma low-density lipoprotein
(LDL) levels, but also the number of small dense LDL particles are involved in the development
of arteriosclerosis. Anion exchange resins can reduce plasma LDL levels and affect LDL particle
size via increasing triglycerides. In the present study, the effects of short-term colestimide
administration on LDL particle size were investigated.
Methods: Obese patients with primary hyperlipidemia (n = 21) were administered 3000mg/day
of colestimide for 1 month and fasting blood was obtained before and after the treatment. LDL
particle size and number were measured by nuclear magnetic resonance (NMR) lipoproﬁle using
magnetic resonance spectroscopy.
Results: Levels of plasma LDL cholesterol decreased from 155.5mg/dl to 128.1mg/dl (p < 0.001)
and levels of apolipoprotein B decreased from 139.2mg/dl to 120.6mg/dl (p < 0.001) by coles-
timide administration. Levels of high-density lipoprotein (HDL) cholesterol and triglyceride were
unaltered. LDL particle size did not change, whereas LDL particle numbers decreased from
1920.3 nmol/l to 1568.8 nmol/l (p < 0.01).
Conclusions: Short-term administration of colestimide to patients with hyperlipidemia reduced
LDL particle numbers. LDL particle size was not changed.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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ntroduction
he method of treating dyslipidemia has been improved
ramatically by the introduction of HMG—CoA reductase
nhibitors (statins). Anion exchange resin agents, which were
nce in the mainstream of treatment of dyslipidemia, have
een replaced by statins mainly due to the required large
osage and their difﬁculty for oral use. However, anion
xchange resins have a primary preventive effect on coro-
ary artery diseases by lowering low-density lipoprotein
LDL) cholesterol levels [1]. Anion exchange resins can be
sed in patients with intolerance to statins or in patients
here statins have limited efﬁcacy [2]. Anion exchange
esins enhance uptake of circulating LDL to cells by increas-
ng the number of LDL receptors in the liver, resulting in
eduction of circulating LDL levels [3]. Because liver choles-
erol synthesis is enhanced and very (V)LDL can be released
o the circulation, the possibility exists that triglyceride, the
ain component of VLDL, may be increased.
In metabolic syndrome, LDL particle size may become
maller with an increase in triglyceride levels. However, very
ew studies have been performed on LDL particle size after
dministration of anion exchange agents. Thus, in this study,
he effects of short-term administration of colestimide on
DL particle size were investigated.
ubjects and methods
atient characteristics
he study protocol was approved by the ethical committee
f the Hokkaido University and was in accordance with the
elsinki Declaration. An anion exchange resin formulation
colestimide, 3000mg/day) was administered for 1 month to
1 obese (as deﬁned by the criteria of Japan Society for the
tudy of Obesity) untreated patients with primary hyperlipi-
emia (61.5± 9.8 years; male/female = 10/11; body height
59.3± 11.0 cm; body weight 71.2± 12.0 kg; body mass
ndex 28.0± 3.2 kg/m2), who visited the Department of
ardiovascular Medicine, Hokkaido University Hospital, as
utpatients and gave informed consent to participate in the
tudy.
Diabetes as deﬁned by the criteria of Japan Diabetes
ociety was found in 6 patients (28.6%). Patients with a his-
ory of ischemic heart disease, peripheral artery obstructive
isease, stroke, renal disease, active liver disease, heart
ailure, and carotid artery stenosis were excluded. Patients
ith type III hyperlipoproteinemia or patients with triglyc-
ride level >400mg/dl were also excluded.
ipid measurements
DL particle size and serum lipid proﬁle [levels of
otal cholesterol, triglyceride, high-density lipoprotein
HDL) cholesterol, LDL cholesterol, remnant-like particle-
holesterol (RLP-C), and apolipoprotein] were compared
efore and after administration of colestimide. Concen-
rations of serum total cholesterol and triglyceride were
etermined enzymatically. HDL cholesterol was determined
y using a homogeneous method (Determiner L HDL-
t
d
m
pN. Kishimoto et al.
, Kyowa Medex, Tokyo, Japan), and concentrations of
polipoproteins (apo) A-I, A-II, B, C-II, C-III, and E were
etermined by turbidmetric immunoassays. LDL choles-
erol concentration was calculated using the formula of
riedewald et al. [4]. RLP-C was measured by using an
mmunoadsorbent method (JIMRO II, Otsuka, Tokyo, Japan).
DL particle size was measured by nuclear magnetic res-
nance (NMR; THE NMR Lipoproﬁle, LipoMed, Inc., Raleigh,
C, USA) [5]. NMR spectroscopy measures the signal emitted
y plasma lipid methyl groups during magnetic resonance
canning. For data evaluation the NMR lipoprotein subfrac-
ions were grouped to lipoprotein class. This resulted in
he following spectra: VLDL (>27.0 nm); intermediate den-
ity lipoprotein (IDL) (23.0—26.9 nm); LDL (18.0—22.9 nm);
nd HDL (7.3—13.0 nm). LDL includes IDL unless otherwise
tated. NMR method is rapid and measures the full spectrum
f the lipoprotein subfraction distribution given as lipopro-
ein particle number for each subclass and the lipoprotein
article size of each lipoprotein subclass at the same time
n a small fresh or frozen sample. NMR method does not
equire non-physiological density gradient centrifugation.
ipoprotein size determined by NMR reﬂects only lipid frac-
ions and somewhat underestimates as compared to the size
etermined by polyacrylamide gel electrophoresis method.
nstead of expressing subclass levels in lipid mass concentra-
ion units (mg/dl cholesterol) as was conventionally done,
hey are given in particle concentration units (nanomoles
f particles per liter, nmol/l) to reﬂect that NMR is actu-
lly measuring LDL particle numbers. Mean particle sizes
nm diameter) were computed as the sum of the diameters
f the individual subpopulations multiplied by their relative
ass percentages as estimated from the amplitudes of their
ethyl NMR signals.
tatistical analysis
he biochemical data of the subjects are presented as
he mean± SD. The variables’ differences before to after
dministration were examined by the Student’s paired t-
est. Two-sided p-values <0.05 were regarded as signiﬁcant.
ll analyses were done with SPSS 10.1 (SPSS Inc., Chicago,
L, USA).
esults
he levels of total cholesterol, LDL cholesterol, and
polipoprotein B were signiﬁcantly improved by the admin-
stration of colestimide (Table 1). Level of RLP-C also tended
o decrease. Level of triglyceride did not differ signiﬁcantly
efore and after treatment. No changes were observed in
he levels of HDL cholesterol and apo A1.
For each lipoprotein particle, neither the mean particle
ize of VLDL nor HDL changed. LDL particles did not decrease
n size (Table 2). On the other hand, there was a signiﬁ-
ant decrease in LDL particle numbers as measured by NMR
Table 2).Furthermore, as to component percentages of LDL par-
icle size, percentage ratio of small size LDL tended to
ecrease from 5.0% to 2.5% (Fig. 1) [6]. Percentage ratio of
edium size LDL tended to increase from 38.6% to 39.3% and
ercentage ratio of large size LDL also tended to increase
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Table 1 Changes in plasma cholesterol, lipoproteins, and other lipids before and after colestimide administration in 21 patients.
Before After p-Value
Total cholesterol (mg/dl) 240.3 ± 28.6 208.2 ± 33.2 <0.001
Triglyceride (mg/dl) 164.3 ± 57.1 167.5 ± 51.4 n.s.
HDL cholesterol (mg/dl) 38.6 ± 9.6 39.3 ± 9.5 n.s.
LDL cholesterol (mg/dl) 155.5 ± 23.2 128.1 ± 28.5 <0.001
Apolipoprotein AI (mg/dl) 126.0 ± 20.3 128.8 ± 20.7 n.s.
Apolipoprotein AII (mg/dl) 26.5 ± 5.1 25.3 ± 5.0 n.s.
Apolipoprotein B (mg/dl) 139.2 ± 17.1 120.6 ± 18.4 <0.001
Apolipoprotein CII (mg/dl) 5.6 ± 2.1 5.5 ± 1.6 n.s.
Apolipoprotein CIII (mg/dl) 10.5 ± 4.0 11.3 ± 3.7 n.s.
Apolipoprotein E (mg/dl) 4.9 ± 0.9 4.6 ± 1.0 n.s.
RLP-C (mg/dl) 8.1 ± 3.2 7.1 ± 2.1 n.s.
Values are the mean± SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein; RLP, remnant-like particle.
Table 2 Changes in mean size and numbers of lipoprotein particles before and after colestimide administration in patients.
Before After p-Value
VLDL particle size (nm) 42.0 ± 6.6 43.6 ± 6.7 n.s.
LDL particle size (nm) 21.2 ± 0.7 21.2 ± 0.5 n.s.
HDL particle size (nm) 9.0 ± 0.6
LDL particle numbers (nmol/l) 1920.3 ± 454.8
Values are the mean± SD. VLDL, very low-density lipoprotein; LDL, low
Figure 1 Changes in lipoprotein content percentage ratios in
each low-density lipoprotein (LDL) particle size category before
and after the administration of colestimide. Percentage ratio
of small size LDL tended to decrease (5.0—2.5%). Percentage
ratio of both medium size LDL (38.6—39.3%) and large size LDL
(50.3—52.1%) tended to increase after treatment. Percentage
ratio of intermediate density lipoprotein (IDL) did not show
any changes (6.1—6.1%). For data evaluation, the nuclear mag-
netic resonance lipoprotein subfractions were grouped into size
groups for LDL lipoprotein class. This resulted in the follow-
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sured by using polyacrylamide gradient gel electrophoresising spectra: IDL (23.0—26.9 nm); large size LDL (21.3—22.9 nm);
medium LDL (19.8—21.2 nm); and small LDL (L1, 18.0—19.7 nm)
[6].
from 50.3% to 52.1% after treatment. Percentage ratio of
IDL did not change from 6.1% to 6.1%.
DiscussionColestimide is non-absorbable and enhances excretion of
bile acids in feces via absorption in the intestinal tract.
This causes inhibition of intestinal circulation of bile acids,
(
m
m
e9.1 ± 0.6 n.s.
1568.8 ± 286.2 p < 0.01
-density lipoprotein; HDL, high-density lipoprotein.
epletion of the cholesterol pool in the liver, increase in
DL receptors, and decrease in circulating LDL cholesterol
evel. Further, it is believed that inhibition of the absorp-
ion of cholesterol derived from food plays a role in the
owering of LDL cholesterol level. On the other hand, the
ossibility exists that LDL particles might decrease in size
ith increase in triglyceride due to re-synthesis of VLDL.
mall dense LDL, which is small and high in density, is a
isk factor for ischemic heart disease [7] and simvastatin
nd bezaﬁbrate have beneﬁcial effects on LDL particle size
8,9]. However, for colestimide, there have been almost
o reports on investigations of its effects on lipid proﬁle,
specially LDL particle size, such as in large-scale clini-
al trials. In the present study, LDL particles were directly
easured using the NMRmethod before and after the admin-
stration of colestimide, making this the ﬁrst report on
hanges in such particles induced by colestimide. Despite a
rief administration period, colestimide lowered LDL choles-
erol but also increased triglyceride slightly. LDL particle
ize was not changed. In this study LDL particle number
as signiﬁcantly decreased to 81.7% of baseline value after
reatment and LDL cholesterol was reduced to 82.8% of
aseline value after treatment. Based on these data it
as expected that LDL particle size was not changed. NMR
ata conﬁrmed that the LDL particle size was indeed not
hanged.
A signiﬁcant increase in LDL particle size is reported with
olestimide administration in patients with normal fasting
lood glucose [10]. LDL particle size has been generally mea-GGE) [11]. Small dense LDL particle size measured by NMR
ethod was 20.5 nm or less, which was smaller than that
easured using GGE method by about 5 nm [12]. Yoshino
t al. reported a signiﬁcant decrease in mobility (Rf) value
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fter colestimide administration, indicating increase in LDL
article size [10]. They used a simple LipoPrint LDL system
Quantimetrix, Redondo Beach, CA, USA), for which a neg-
tive correlation to those obtained with the GGE method
as been shown. They also assumed that the LDL fraction
ith Rf of 0.40 or higher contained small dense LDL [13].
n their system Rf of 0.40 or higher corresponds with small
ense LDL with a particle size of 25.5 nm or below. They only
ssumed that signiﬁcant reduction of Rf values after coles-
imide administration implicated an increase in LDL particle
ize. Thus, direct evidence of the improvement in LDL par-
icle size was not present in their study. The decrease rate
n small size LDL appeared to be larger than that in RLP-C.
olestimide ameliorates glucose metabolism in mice [14].
signiﬁcant increase in LDL particle size is reported with
olestimide administration in patients with normal fasting
lood glucose [10]. The patients in this study were obese,
nd diabetes was found in 6 patients. The differences in clin-
cal characteristics may have affected the response of LDL
o colestimide. Further investigation with larger number of
atients will be necessary with respect to the effect on LDL
nd non-lipid parameters in the subgroup with high RLP-C or
iabetes.
imitations
n this study, mean LDL particle size before colestimide
dministration was not particularly small (21.2 nm), and the
ontent of large LDL in LDL was 50% or higher while the con-
ent of small LDL in LDL was quite small at 5.0%. In addition,
t is speculated that the short period of administration and
elatively small number of subjects may have contributed
o the lack of demonstration of increase in particle size. It
as been suggested that the increase in triglyceride level
y colestimide administration does not decrease LDL par-
icle size. Elucidation of the effects of simvastatin and
ezaﬁbrate, which have beneﬁcial effects on LDL particle
ize [8,9] and on LDL particle numbers will be also neces-
ary.
onclusion
n summary, our ﬁndings suggest that colestimide not only
owers the levels of LDL cholesterol and apolipoprotein B,
ut also reduces LDL particle numbers without reducing LDL
article size. Statins may cause allergy or may not be suf-
ciently effective in some patients. Colestimide may be
ffective in improving LDL cholesterol in such patients. LDL
article size and number provide independent measures of
therogenicity and are strong predictors of cardiovascular
isease [15]. Because colestimide exhibited insufﬁcient efﬁ-
acy for increase in LDL particle size, further investigation
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